# EUROPA (NCT04134598)

> ExclUsive endocRine Therapy Or Radiation theraPy for Women Aged ≥70 Years Early Stage Breast Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04134598
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Azienda Ospedaliero-Universitaria Careggi
- Conditions: Breast Cancer
- Interventions: Breast irradiation (RT); Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
- Enrollment: 926
- Primary outcome: Patient reported outcome measures (PROM) HRQoL as assessed by European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ) C30
- Primary outcome: Time to ipsilateral breast tumor recurrence (IBTR)

## Commentary we found

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=europa-nct04134598